Astellas Pharma Aktie
WKN DE: A0YGQP / ISIN: US04623U1025
|
05.02.2025 11:05:11
|
Astellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In Japan
(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for the treatment of geographic atrophy or dry age-related macular degeneration or AMD.
Avacincaptad is a synthetic aptamer that inhibits the complement C5 protein.
Astellas said the Ministry of Health, Labour and Welfare will evaluate ACP as a potential first treatment for patients with geographic atrophy. The company will also evaluate secondary to age-related macular degeneration in Japan.
Geographic atrophy is a progressive form of AMD that can cause irreversible vision loss, with no treatments currently approved outside the US or Australia.
The NDA submission is based on results of overseas clinical trials, including the GATHER1 and GATHER2 randomized, sham-controlled clinical trials.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Shmehr Nachrichten
|
16.10.25 |
Erste Schätzungen: Astellas Pharma stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
|
29.07.25 |
Ausblick: Astellas Pharma gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
|
16.07.25 |
Erste Schätzungen: Astellas Pharma gewährt Anlegern Blick in die Bücher (finanzen.net) |